Form 4: Mineralys Therapeutics Insider Trades Under 10b5-1 Plan

Mineralys Therapeutics Chief Medical Officer, Rodman David Malcom, executed trades involving common stock and stock options under a pre-established Rule 10b5-1 trading plan.

Summary

• Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions on April 9, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 6, 2025.
• Malcom acquired 2,170 shares of common stock at a price of $16 per share.
• He also disposed of 2,170 shares of common stock at a price of $27.38 per share.
• Following these transactions, Malcom beneficially owns 76,140 shares of common stock.
• A stock option for 2,170 shares, with an exercise price of $16, was also part of the reported activity, with 21,706 derivative securities now beneficially owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions executed under a pre-defined plan, without indicating significant positive or negative developments for the company.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-knowledge-based trading.
• The acquisition of shares at a lower price ($16) and disposition at a higher price ($27.38) suggests a profitable execution within the plan.
• The continued beneficial ownership of a significant number of shares (76,140) indicates ongoing commitment to the company.

Negatives

• The disposition of 2,170 shares represents a reduction in the reporting person's direct holdings.
• The sale price of $27.38 is lower than the potential future value if the company's stock performs well.

Risks

• The Rule 10b5-1 plan itself is subject to specific requirements and potential scrutiny if not properly implemented or followed.
• Future stock price performance is inherently uncertain and could impact the value of remaining holdings and options.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that insider trading reports, particularly those executed under Rule 10b5-1 plans, are common for executives in the biotechnology and pharmaceutical sectors as they navigate stock vesting and personal financial planning while adhering to regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: The disposition of shares by an executive may be interpreted in various ways, but the use of a 10b5-1 plan mitigates concerns about insider trading. The continued significant ownership suggests ongoing commitment.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Continued monitoring of insider transactions for any significant changes in beneficial ownership or trading patterns.

Key Dates

Keywords

SEC Form 4, Insider Trading, Rule 10b5-1, Mineralys Therapeutics, MLYS, Stock Options, Beneficial Ownership, Securities Transaction, Executive Trading